-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320

Benzinga·10/14/2026 17:58:02
Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $340 to $320.